A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Purpose
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: - an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or - TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together. Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting). The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it. Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health. Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months. Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned. During the study, the study team will: - Check vital signs such as blood pressure and heart rate - Examine the participants' heart health using an electrocardiogram (ECG) - Take blood samples - Ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
Conditions
- Prevention of Ischemic Stroke
- Acute Non-cardioembolic Ischemic Stroke
- High-risk Transient Ischemic Attack
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must be ≥ 18 years of age - Acute non-cardioembolic stroke or high-risk TIA - Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct
Exclusion Criteria
- Ischemic stroke ≤ 7 days before the index event - Index stroke following procedures or strokes due to other rare causes - History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Asundexian |
Participants will receive asundexian. |
|
Placebo Comparator Placebo |
Participants will receive placebo. |
|
Recruiting Locations
Fairhope, Alabama 36532
Phoenix, Arizona 85013
Tucson, Arizona 85724-5023
Little Rock, Arkansas 72205
Long Beach, California 90806
Los Angeles, California 90027
Los Angeles, California 90033
Los Angeles, California 90095
Orange, California 92868
Torrance, California 90502
Bridgeport, Connecticut 06606
New Haven, Connecticut 06519
Newark, Delaware 19718
Atlantis, Florida 33462
Boynton Beach, Florida 33472
Bradenton, Florida 34243
Clearwater, Florida 33756
Gainesville, Florida 32608
Sarasota, Florida 34239
Tampa, Florida 33606
Chicago, Illinois 60612
Chicago, Illinois 60637
Maywood, Illinois 60153
Rockford, Illinois 61114
Springfield, Illinois 62769
New Orleans, Louisiana 70121-2429
Baltimore, Maryland 21201
Bethesda, Maryland 20817
Boston, Massachusetts 02111
Detroit, Michigan 48202
East Lansing, Michigan 48824
Pontiac, Michigan 48341
Golden Valley, Minnesota 55422
Rochester, Minnesota 55902
Kansas City, Missouri 64111
Kansas City, Missouri 64128
Saint Louis, Missouri 63110
Saint Louis, Missouri 63141
Lebanon, New Hampshire 03756
Albany, New York 12208
Brooklyn, New York 11220
Brooklyn, New York 11234
Great Neck, New York 11021
Hawthorne, New York 10532
Poughkeepsie, New York 12601
Asheville, North Carolina 28801
Durham, North Carolina 27710
Greensboro, North Carolina 27405
Greenville, North Carolina 27834
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27157
Cleveland, Ohio 44195
Columbus, Ohio 43210
Columbus, Ohio 43214
Dayton, Ohio 45409
Kettering, Ohio 45429
Toledo, Ohio 43606
Toledo, Ohio 43608
Youngstown, Ohio 44504
Oklahoma City, Oklahoma 73104
Portland, Oregon 97239
Allentown, Pennsylvania 18103
Erie, Pennsylvania 16507
Harrisburg, Pennsylvania 17101
Hershey, Pennsylvania 17033
Lancaster, Pennsylvania 17601
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19140
Providence, Rhode Island 20903
Charleston, South Carolina 29425
Greenville, South Carolina 29605
Chattanooga, Tennessee 37403
Knoxville, Tennessee 37920
Dallas, Texas 75204
Dallas, Texas 75390
Edinburg, Texas 78539
Fort Worth, Texas 76104
Houston, Texas 77030
Houston, Texas 77030
Plano, Texas 75093
San Antonio, Texas 78229
Temple, Texas 76508
Murray, Utah 84107
Henrico, Virginia 23229
Huntington, West Virginia 25701
Milwaukee, Wisconsin 53226
More Details
- NCT ID
- NCT05686070
- Status
- Recruiting
- Sponsor
- Bayer